Researchers at the University of Texas at Austin have a nasal vaccine for the Ebola virus in development that has provided long-term protection for non-human primates against the virus.
Small pre-clinical study results are the first to show that a single dose of a non-injectable vaccine for Ebola could have a longer duration. The research is being presented Nov. 5 at the 2014 American Association of Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition in San Diego Nov. 2-6. The AAPS conference is the world’s largest pharmaceutical sciences meeting.
The test vaccine increased survival of immunized primates from 67 percent to 100 percent after exposure to 1,000 plaque forming units of Ebola Zaire 150 days after immunization. This compared with only 50 percent of the primates that received an injection of the vaccine surviving the Ebola exposure.
